Voacangine and Coronaridine: The Alkaloids Hiding in Ibogaine's Shadow
Ask ten ibogaine clinics where their supply comes from and most will say "plant extract" without specifying which plant. That vagueness matters more than it sounds. A meaningful share of the ibogaine used in treatment today never touches a Tabernanthe iboga root at all. It starts as voacangine, an alkaloid from an entirely different tree, and gets converted in a lab. Its close cousin coronaridine, meanwhile, has become the chemical backbone of one of the most closely watched experimental addiction drugs in development. Few sites covering ibogaine mention either compound in any depth, which is strange given how much of the field's future runs through them.
What Voacangine Actually Is
Voacangine is the dominant alkaloid in the bark of Voacanga africana, a tree that grows across a much wider swath of West and Central Africa than Tabernanthe iboga. Structurally, the two molecules are very close relatives: voacangine differs from ibogaine mainly by carrying an extra carbomethoxy group at one position on the shared ibogamine skeleton. Remove that group through saponification and mild acid treatment, a reaction documented in a French pharmaceutical patent filed by chemists Robert Goutarel and Marie-Madeleine Janot, and what remains is ibogaine itself.
That patent, filed decades before ibogaine clinics existed, made an argument that reads almost like a sustainability pitch today: voacangine from Voacanga bark was more practical to produce than extracting ibogaine directly from iboga root, because the tree is more widespread, the bark regrows after harvest, and the plant is not destroyed in the process. Root harvesting of Tabernanthe iboga kills the plant. Bark harvesting of Voacanga africana, done carefully, does not.
A 1998 discussion that circulated on the ibogaine research mailing list of that era laid out the numbers plainly: published pharmacognosy studies put Voacanga africana root bark alkaloid content at 5 to 10 percent, compared with roughly 3 grams of ibogaine per kilogram in Tabernanthe iboga root. The chemist behind that post summarized the patent's core finding in a single line: strip the extra group off voacangine "and ibogaine is obtained." It is not a complicated transformation chemically. It is, however, a transformation that requires lab equipment and controlled conditions, not something achievable by soaking bark in water at home.
The 1998 Tincture That Wasn't What It Claimed
The gap between a plant containing an alkaloid and a product actually delivering a useful dose of it showed up in a real commercial case that played out on that same mailing list. A company selling a "concentrated" Voacanga africana tincture advertised it as a traditional West African stimulant. When list members tested a sample, they found it contained less than 200 milligrams of dissolved alkaloid material per ounce. Given the 5 to 10 percent alkaloid content reported for the raw bark, that worked out to an extract roughly ten times more dilute than the source material, made from less than three grams of actual bark per ounce of tincture sold.
Nobody in that thread accused the company of fraud outright, but the episode is a useful case study in why "contains voacangine" or "contains ibogaine" on a label means almost nothing without a stated concentration. The same question applies to supplements and extracts sold online today. A product can be technically truthful and pharmacologically irrelevant at the same time.
Coronaridine: The Alkaloid Behind a Different Drug Entirely
Coronaridine is voacangine's close relative, present in many of the same plants, and it has taken a separate path into modern research. In 1994, pharmacologist Stanley Glick's lab at Albany Medical College published a study testing a panel of iboga alkaloids, including ibogaine, tabernanthine, and both enantiomers of coronaridine, on morphine and cocaine self-administration in rats at doses between 2.5 and 80 milligrams per kilogram. All of them reduced drug intake. But coronaridine and its relative ibogamine stood apart in one respect: they produced very weak or no tremors, while ibogaine and tabernanthine reliably caused tremors lasting two to three hours.
That difference pointed Glick's team toward coronaridine rather than ibogaine as a starting point for drug design. Two years later, in 1996, the lab synthesized 18-methoxycoronaridine, known as 18-MC, now carrying the international nonproprietary name zolunicant. It is, by chemical lineage, a coronaridine derivative, not an ibogaine derivative, despite routinely getting described in coverage as "an ibogaine analog." The distinction is not pedantic. 18-MC acts primarily as an antagonist at alpha-3-beta-4 nicotinic receptors, with a reported binding affinity (IC50) of 0.75 micromolar, a mechanism distinct from how ibogaine itself appears to work, and unlike ibogaine it shows no measurable affinity for the serotonin transporter or NMDA channels. It does not reliably produce the hours-long visionary experience associated with ibogaine treatment. The compound was filed as an Investigational New Drug with the FDA on February 9, 2014, under the developmental name MM-110 after MindMed acquired the program from Savant HWP in 2019.
The clinical record since then has been mixed. MindMed completed a Phase 1 trial in 108 healthy volunteers in 2022, reporting favorable safety, tolerability, and pharmacokinetics for MM-110 as a candidate for opioid withdrawal. That result did not translate into continued investment: in 2023 MindMed shelved the program as part of a broader pipeline reprioritization, and as of this writing the company has said it is looking for outside funding or a partner to restart development rather than funding it directly. A separate line of research has kept 18-MC alive for an entirely different indication. A 2026 study published in Frontiers in Pharmacology reported that oral 18-MC showed potent antileishmanial activity in both rodent and primate models of cutaneous leishmaniasis, with a safety profile the authors judged compatible with moving to first-in-human testing for that indication. So the compound's nearest-term path forward, if it has one, may run through a tropical parasitic disease rather than the addiction indication it was originally designed for.
Why This Matters for Anyone Researching Ibogaine Treatment
Three practical points follow from the voacangine and coronaridine story. First, semisynthetic ibogaine made from voacangine is not a lesser or counterfeit version of the "real thing." It is the same molecule, produced through an established, patent-documented chemical route, and arguably represents a more sustainable supply chain than root harvesting. Second, products marketed around voacangine, coronaridine, or Voacanga extracts are not interchangeable with pharmaceutical-grade ibogaine, and the 1998 tincture case is a reminder that concentration claims on unregulated products deserve skepticism. Third, 18-MC and similar coronaridine-derived compounds are not ibogaine, do not currently have any approved clinical use, and anyone encountering marketing that blurs this line should treat it as a red flag rather than a selling point.
Where the Research Stands
None of this settles the deeper pharmacological question. Decades after Glick's original tremor comparison, researchers still have not fully resolved why structurally similar iboga alkaloids produce such different profiles of hallucination, tremor, and anti-addictive effect. A sustainability case can be made for voacangine-derived ibogaine on conservation grounds alone, since wild Tabernanthe iboga populations grow slowly and face real harvesting pressure, a concern the Bwiti communities who depend on the plant have raised directly. But a chemical identical to ibogaine, however it is sourced, still carries the same cardiac risks and still requires the same medical screening. Changing the supply chain does not change the safety profile of the final molecule.
Practical Takeaway
If you are evaluating a treatment provider, it is reasonable to ask directly whether their ibogaine is extracted from Tabernanthe iboga root, produced semisynthetically from voacangine, or fully synthesized, and whether they can provide any documentation of purity testing. A provider who cannot answer that question, or who conflates coronaridine-derived research compounds with available ibogaine treatment, has not done the homework a serious clinic should have done.